Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has earned a consensus rating of "Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $20.83.

A number of research firms recently issued reports on REPL. Cantor Fitzgerald began coverage on Replimune Group in a report on Friday, June 20th. They set an "overweight" rating on the stock. Piper Sandler lifted their target price on Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a report on Monday, June 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,952 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the transaction, the insider now owns 146,933 shares in the company, valued at $1,184,279.98. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Philip Astley-Sparke sold 32,279 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the sale, the director now owns 1,405,071 shares of the company's stock, valued at $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,907 shares of company stock worth $603,655 in the last quarter. 8.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently bought and sold shares of the business. Optimize Financial Inc acquired a new stake in Replimune Group during the 1st quarter worth about $140,000. Exome Asset Management LLC boosted its position in Replimune Group by 438.6% during the 1st quarter. Exome Asset Management LLC now owns 294,846 shares of the company's stock worth $2,875,000 after acquiring an additional 240,108 shares during the period. Goldman Sachs Group Inc. boosted its position in Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after acquiring an additional 119,145 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Replimune Group during the 1st quarter worth about $343,000. Finally, Parkman Healthcare Partners LLC boosted its position in Replimune Group by 9.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company's stock worth $9,266,000 after acquiring an additional 80,640 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of REPL opened at $9.75 on Wednesday. The firm has a market capitalization of $751.63 million, a price-to-earnings ratio of -3.18 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95. Replimune Group has a one year low of $6.44 and a one year high of $17.00. The stock's fifty day moving average is $8.91 and its 200-day moving average is $10.72.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the business earned ($0.25) earnings per share. Equities analysts anticipate that Replimune Group will post -2.97 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.